Soft Tissue Sarcoma
5 competing products in clinical development for Soft Tissue Sarcoma.
Pipeline by Phase
Phase 11
Phase 23
Phase 31
All Products (5)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV | Eisai | Phase 3 | Completed | 40 |
| E7389 | Eisai | Phase 2 | Completed | 35 |
| eribulin mesylate | Eisai | Phase 2 | Completed | 35 |
| Anlotinib Hydrochloride | Sun Pharmaceutical | Phase 2 | UNKNOWN | 31 |
| Olaratumab + Doxorubicin + Ifosfamide + Mesna | Eli Lilly | Phase 1 | Completed | 29 |